The COVID-19 Pandemic: White House Coronavirus Task Force to Shift Focus; Genetic Analysis Confirms Virus Started in 2019; and More – DocWire News

World News:

The world is closing in on yet another grim milestone as COVID-19 has infected almost 4 million people worldwide. Worldometer now reports 3.7 million confirmed cases, with the novel virus SARS-CoV-2 now responsible for the deaths of almost 260,000 people across the globe.

Outside of the US, the countries with the most confirmed cases are:

UK Scientist Steps Down After Breaking Lockdown Rules He Helped Develop

The United Kingdoms scientific adviser, who helped architect the UKs lockdown rules, resigned after he broke his own protocols. Professor Neil Ferguson, the leading epidemiologist who advised the British government on its COVID-19 response, stepped down after a story broke in The Telegraph that he allowed his reported lover to visit him at home, thus breaking lockdown orders. London police commented by saying: We remain committed to our role in supporting adherence to government guidance and have made it clear that our starting position is explaining the need to follow the regulations with anyone who is in breach in order to keep people safe and protect the National Health Service (NHS).

National News:

Wednesday, May 6, 2020

Over 70,000 US Deaths

COVID-19 has now killed over 72,000 people in the United States as of Wednesday, May 6. There are over 1.2 million confirmed infections. The US epicenter of New York now reports 330,139 confirmed cases and 25,436 deaths while second leading New Jersey now has 131,705 confirmed cases and 8,292 deaths.

Outside of NY and NJ, the US states with the most confirmed infections are:

President Donald Trump said on Wednesday that the White House coronavirus task force will continue working indefinitely, reversing an initial decision he made on Tuesday to phase out the team in the coming weeks. Trump said that the group, said by Vice President Mike Pence, has done a fantastic job of bringing together vast highly complex resources, such as ventilators, face masks and testing systems. Because of this success, the Task Force will continue on indefinitely with its focus on SAFETY & OPENING UP OUR COUNTRY AGAIN, the president tweeted. Trump added that, We may add or subtract peopleto it, as appropriate. The Task Force will also be very focused on Vaccines & Therapeutics. Thank you!

A new genetic analysis of SARS-CoV-2, the virus that causes the disease COVID-19, shows that coronavirus started circulating in people late last year, and spread extremely quickly after the first infection, according to a CNN report.. This dispels any rumors that the virus had been around earlier than 2019. The analysis also found no evidence that the virus is becoming more transmissible. The virus is changing, but this in itself does not mean its getting worse, genetics researcher Francois Balloux of the University College London Genetics Institute told CNN.

The US Center for Disease Control and Prevention says that at least 4,893 incarcerated or detained people have been infected with COVID-19. Moreover, the CDC reports that at least 2,778 staff members have tested positive for the respiratory disease, resulting in 15 deaths. Approximately one half of facilities with COVID-19 cases reported them among staff members but not among incarcerated persons, the report said. Because staff members move between correctional facilities and their communities daily, they might be an important source of virus introduction into facilities.

Tuesday, May 5, 2020

Monday, May 4, 2020

Friday, May 1, 2020

Friday, May 1, 2020

As most US states begin easing their lockdown restrictions, its apparent that the US is still not of the virus grip. There are now over 1.1 million confirmed cases in the US and over 64,000 deaths. The countrys epicenter, New York, now reports 310,839 confirmed cases and 24,069 deaths. The nations capital, Washington DC, has seen an uptick in cases over the past seven weeks, and reported 335 new cases on Friday its biggest single day rise.

The US states outside of New York with the highest confirmed cases remain:

Dr. Anthony Fauci said the Trump administration is ramping up efforts for developing a coronavirus vaccine, and one could be available by January, the NY Post reports. We want to go quickly, but we want to make sure its safe and its effective, Faucisaid on NBCs Today showon Thursday. I think that is doable if things fall in the right place.

The US Centers for Disease Control and Prevention how the US deals with the COVID-19 pandemic in the coming weeks will be critical to how the virus will evolve come the fall season. I do think that what we do this summer is going to be critical, said Dr. Ann Schuchat, CDC principal deputy director in an interview with JAMA Network. The more we intensify the testing and expand the public health capacity and assure that our hospital capacity and material to support the hospitals is adequate or has excess, the better were going to be in the fall.

The COVID-19 Pandemic: April Round-up

Heres a full wrap-up of COVID-19 happenings from the month of March.

The COVID-19 Pandemic March Round-up: Coronavirus Declared a Pandemic; People, Businesses and Economies Devastated

DocWire News will provide breaking updates on the COVID-19 pandemic as they become available.

Read more:
The COVID-19 Pandemic: White House Coronavirus Task Force to Shift Focus; Genetic Analysis Confirms Virus Started in 2019; and More - DocWire News

Breaking the Code: A lifetime of pain, due to genetic drug intolerance – FirstCoastNews.com WTLV-WJXX

JACKSONVILLE, Fla. For Linda Armstrong, the pain started 25 years ago with a truck going 45 miles an hour. It left her with severe neurological and brain injuries.

On a scale of one to 10, she said, There are days when its 10. I mean you literally cant move.

Like millions of Americans, she was prescribed opioids -- Vicodin, Dilaudid, Percocet but the pain persisted.

I would get some relief, but nothing that ever really made me functional, she said, "and it always made me nauseous.

Armstrongs lackluster response to pain medications had been a reality since she was a child. Once, getting a cavity filled, she recalls, I had to have 10 shots for one filling because it just would not numb.

Her resistance to drugs was simply anecdotal until she visited her doctor in October. Under new Centers for Disease Control and Prevention guidelines, doctors test opioid patients both for the presence of illegal drugs, and to ensure they are taking and not selling their pain meds.

Her test? Completely negative. There were no drugs of any type in my system.

Initially, her doctor wrote it off as a fluke.

When it happened a second time, Armstrong explained, her doctor said Linda we have to talk about this.

She took another test this time going so far as to take pills while her doctor watched. She even got her hair tested.

Still: Negative.

Fortunately, Armstrong has had the same doctor since the mid-'90s, and rather than doubting her, she worked to help get answers. She ordered a genetic test, which revealed significant abnormalities -- including in an enzyme called CYP2d6, which metabolizes opioids.

The test revealed something researchers in the field of pharmacogenomics know, but few patients do. People do not respond to drugs in the same way, explains Standford University researcher Dr. Russ Altman in a Ted Talk. Some people get no pain relief at all.

Armstrongs genetic test showed she was a hyper-metabolizer of opioids an issue that creates problems beyond pain. As Altman says, there are only two things a doctor can think when a patient complains they arent getting relief from opioids.

I could think this person is a CYPD2d6 non-responder, or I could think this is a trouble-making drug-seeker who wants something stronger, Altman said. Most doctors think the latter.

Armstrongs case is dramatic but not unusual. Dr Liewei Wang at Mayo Clinic in Rochester, Minn., is a leading researcher in pharmacogenomics research into the interaction of genes and drugs. She says 99 percent of people have at least one genetic variant that affects drug response. Response is variable, and in some cases not desirable.

Genetic testing can predict who may or may not respond, she said, and for those who dont respond -- are there alternative therapies?

In some cases, the wrong drug can be fatal. Already, hospitals like UF Health test cardiac patients before surgery for a gene that complicates blood clotting.

And some fields, like oncology and psychiatry, routinely use genetic tests to prescribe drugs. But most patients arent aware such tests even exist.

Jacksonville Pharmacist Todd Troxell believes genetic testing is the key to more effective prescribing. When you go get your glasses we dont just say, pick something up and go home. We get your prescription, he says. You cant see out of myglasses.

After looking at Armstrongs test, Troxell was able to steer her to a different pain medication that is working. I could tell from what she had on her report she wasnt going to be able to take certain medications.

Troxell would like to see genetic testing more widely available -- and comprehensible. Companies focused on translating dense genetic code into pharmaceutical recommendations were effectively shut down by the FDA in 2018. The agency worriedthe tests could pose significant public health concerns as inaccurate test results could impact the decision-making of healthcare providers and patients in ways that are seriously detrimental to patient health.

The agency walked that back slightly earlier this year, creating a Table of Pharmacogenetic Associations, which lists gene-drug interactions the agency believes are based on sufficient scientific evidence based on published literature.

For now, a genetic test needs to be ordered by a physician, who may or may not be able to interpret the code. And genetics remains just one element that doctors and patients should consider, including age, weight and environmental factors.

But patients like Armstrong say breaking the genetic code shouldnt be a secret it could literally spare them a lifetime of pain. Given the chance early on, she said, I would have had that test done in a heartbeat.

See the rest here:
Breaking the Code: A lifetime of pain, due to genetic drug intolerance - FirstCoastNews.com WTLV-WJXX

Fertility treatment and coronavirus: The Covid-19 baby boom jokes are hard to take – The Irish Times

The rest of the country only now have the experience of living with life on hold something Ive been dealing with for nearly three years, as well as my grief for my lost babies. This lockdown will end for most soon. Not so for us, says Elizabeth.

The emotional and psychological toll of undergoing fertility treatment is, she says, its own kind of lockdown.

In March, what Elizabeth describes as the lonely and heartbreaking wait for a baby was thrown into further uncertainty, when the European Society of Human Reproduction and Embryology (ESHRE) recommended that all fertility patients considering or planning treatment, even if they do not meet the diagnostic criteria for Covid-19 infection, should avoid becoming pregnant.

Patients whose treatment was already under way were advised to defer. But no such advice was given to those who did not need assisted reproductive treatment (ART) to become pregnant.

In March, the European Centre for Disease Control advised that there is no current evidence .. that infection with Covid-19 during pregnancy has a negative effect on the foetus no evidence of transmission of Covid-19 from mother to baby during pregnancy.

This caused distress and confusion for those undergoing treatment. I feel very discriminated against because there was no advice for normal women not to get pregnant, says Elizabeth.

Dr John Kennedy, medical director of the Sims Fertility Clinic in Dublin, says that the decision by Irish clinics to close was made in the national interest. Nobody actually formally directed us to close. But of course it is impossible to practice fertility treatment and maintain social distancing.

Fertility clinics were not originally classified as essential services. But the longer this goes on, the more essential we become, he says.

Last week, the ESHRE recommendations were updated to state that the pandemic is stabilising and the return to normal daily life will also see the need to restart the provision of ART treatments. The majority of Irish fertility clinics are planning to reopen from next week.

Even so, there remains a lot of uncertainty for the estimated 5,000-6,000 people who undergo fertility treatment in Ireland each year. Even before Elizabeths donor egg treatment was postponed, she had already experienced long delays including the nine months it took from her initial consultation to embryo transfer, a cycle which sadly ended in miscarriage.

At 43, she is acutely conscious of time passing. I havent had any updates from my clinic, just that theyll be contacting everyone. Im really hoping I can get started in June. Time goes by very slowly for women like me, and there can be many obstacles and delays.

The jokes about a Covid-19 baby boom are hard to take, she says.

Its time-sensitive, especially for the patients in their 40s. Its enough to make your mental wellbeing really poor, says Dr Bart Kuczera of the Beacon Care Fertility Clinic, which will also reopen next week.

But while the clinic will be open, he warns that you wont be able to start on Tuesday and have all the services available on Wednesday. Fertility cycles follow human reproductive cycles. So it will take at least a month for everything to be back.

For the clinics to reopen, major changes have had to be made in their operation, says Kennedy. Were completely changing how we work: longer days with less staff; theres going to be social distancing where possible for staff and patients; theres going to be appropriate use of personal protective equipment (PPE) which were in the process of sourcing.

Consultations will be virtual where possible, and some supportive drug treatments like immunotherapy and steroid treatment, wont be immediately available. All of the core things egg collection, ICSI, pre-implantation genetic screening will be proceeding as normal.

The early advice from ESHRE, that candidates for fertility treatment should avoid becoming pregnant, has left some women with lingering worries about potential risks. Every answer anybody gives has an asterisk beside it. We just dont know for sure. We think there arent any impacts unlike Sars and Mers, there doesnt appear to be an increased risk. It all appears safe, Kennedy says.

During recent virtual consultations, Kuczera noticed a sharp increase in the number of enquiries about egg freezing suggesting that some women were worried about a risk of becoming pregnant now, but wanted to try to protect their chances in the future. Half of the initial consultations were about egg freezing.

Even when the Irish clinics are once again up and running, for those had been undergoing treatment abroad, there are likely to be further delays.

Miriam travelled to Prague in the final days before international flights stopped so that she could undergo egg retrieval. She is very grateful for the care she received and has no regrets about her choice to undergo IVF there. But, she says, now we have no clue when we might get there to retrieve our embryos. It costs approximately 1,500 to have them shipped, and who knows the risks of that. I hope the governments of both countries recognise the trauma the ESHRE [recommendations have] caused to women like myself.

The Irish Times recently published a letter from another woman, Sarah K, describing the impact of the closure of clinics on her. Sarah K says now: Along with the universal uncertainty ... fertility patients have had to bear the added uncertainty as to whether this delay in treatment will affect their chance of becoming a parent. Im 42 and started this journey over two years ago. I never ever thought I would be still here, in this horrendous, anxiety-filled holding pattern.

As with everyone who spoke to The Irish Times, Sarah K is relieved at the updated ESHRE guidelines. Still, the waiting game goes on. Im still not sure as to when I will get to do my embryo transfer. I can only hope it is soon. Some might think it is only a few months delay, but for me every hour, day, month delay is an hour, a day and a month I wont have with my much longed-for child, and my parents wont have with their much sought after grandchild.

Names of those undergoing fertility treatment have been withheld to protect their privacy

Read the original:
Fertility treatment and coronavirus: The Covid-19 baby boom jokes are hard to take - The Irish Times

What have couples been doing in lockdown? We might know in nine months – The Irish Times

Binge watching box sets, doing jigsaws and sharing almost every human activity possible through video apps are some of the most talked about ways of connecting and alleviating boredom during the coronavirus shutdown.

But what else are couples doing more of behind closed doors?

Maybe nine months will tell.

There has been plenty of light-hearted chatter predicting a wave of coronababies around Christmas and into 2021. A UK discount chain reported, with some glee, towards the end of April that sales of pregnancy test kits were up 25 per cent since the lockdown had begun in Britain on March 23rd.

However, while each pregnancy is ultimately the responsibility of just two people, whats going on in the wider society and economy have a huge bearing on a countrys birth rate. The current crisis is unprecedented and the ramifications are only starting to unfold.

We can only speculate on what impact the Covid-19 era might have, for better or for worse, on procreation in Ireland.

Here are some factors to consider:

At the outset, its important to understand the distinction between these two measurements when talking about increases and decreases in our baby population.

The fertility rate is the average number of children born to women of childbearing age (15-44), while the number of births is recorded as the number of live births per 1,000 of the population each year.

Here in Ireland, our birth numbers have shot up and down in recent decades while our fertility rate has slowly drifted downwards.

We had the highest birth rate in the EU in 2018, with 12.5 births per 1,000 residents while Italy recorded the lowest, at 7.3 per 1,000. However, this is primarily shaped by demographics (see below) rather than personal decision-making about whether or not to start, or enlarge, a family.

An EU comparison of fertility rates for 2017 showed Ireland had the third highest fertility rate, with 1.77 live births per woman, behind France, which topped the list with 1.90 live births per woman, and Sweden fractionally ahead of us with 1.78.

Sixty years ago, our fertility rate was 3.78 births per woman in 1960, the highest in Europe, and we held on to that top spot through 1970 and 1980 but by 1990 our fertility rate of 2.11 trailed that of Cyprus, Iceland and Sweden.

One of the biggest influences on Ireland in the past three decades has been migration, explains Prof Tony Fahey, Professor of Social Policy in UCD, and its effects are seen clearly in the maternity hospitals.

While the propensity of each woman to have children hasnt changed that much over the last 30 years, the number of children who have been born has changed enormously, he points out.

The Republics highest number of births in the 20th century was in 1980, at 74,064 according to CSO figures, and that fell to a low of just over 48,000 in 1994 reflecting the 1980s tide of emigration until a new peak of 75,554 births was reached in 2009.

The upsurge from the mid-1990s was driven entirely by the inflow of women in their late 20s, early 30s, so it was far more women having children, rather than women having more children, says Fahey. The tendency of the average woman to have children hasnt changed very much and has continued to be relatively high in Ireland.

In considering the impact of the coronavirus, he says its interesting to note that this pattern of childbearing was not affected much by the financial crisis in 2008 to 2012.

It did edge down a little, but you didnt get the kind of collapse you got in southern Europe and eastern Asia. We have never had a fall like that in Ireland but that could still happen.

Inward or outward migration, post-Covid-19, will depend not just on what happens to the economy in Ireland but also its relative performance to that of other countries.

We could have another bout of inward migration, or it could be flat, or, if recovery is stronger elsewhere sooner, we could have people leaving Ireland again, which would push the birth rate down again.

How was it for you? The change of life imposed by Covid-19 that is. Mixed anecdotal messages about increased or decreased sex drive could be broadly explained by individual responses to changes in circumstances and with whom youre sharing your home.

Just because many cohabiting couples have had more time and opportunity for sex, doesnt mean they wanted it. For some the novelty of change in routine, with perhaps more sleep, no commute and the relief of being removed from the communal workplace, may have been invigorating. For others, the heightened anxiety is paralysing; or maybe its the exhausting effect of ever-present children.

Stress has an impact on intimacy and desire, says Dublin psychotherapist and couples counsellor Bernadette Ryan, who points to the fear engendered by the pandemic. Suddenly, our bodies have become our enemy and that can bring a lot of anxieties up for people; those kinds of things impact on sexual intimacy.

Sex therapist Diane Gleim, writing on the effect of this time on libido, explains: A persons sex drive needs just enough anxiety/tension/uncertainty to get activated but not too much anxiety/tension/uncertainty or else the person can get overwhelmed, flooded, and then sex drive goes underground.

Its a spectrum, she says in Psychology Today, on which any one of us can move up and down, depending on how youre coping mentally with the pandemic fallout.

With short-term national emergencies in the recent past, such as the crippling snowfalls in February, 2018, courtesy of The Beast from the East, there was an air of excitement, says Ryan about battening down the hatches for a couple of days and that might heighten the sense of wanting to be intimate. This is different; this is endless and we dont know what the new normal is going to be.

Routines and distractions for all of us have radically changed, which alters the dynamics of every relationship. Sex tends to be the thing that goes on the back burner at times of stress, she says, and if it has for you, that is fine dont feel under pressure.

Ryan expects a post-Covid-19 surge in demand for counselling at her Ranelagh practice (dsixcounselling@gmail.com), fearing that the pressure of living with the restrictions will have exacerbated cracks couples might have had in their relationship.

For people cooped up with small children in small places, its tough, she adds. It really will test the mettle of the relationship.

Fertility experts say that couples often dont have sex frequently enough to give themselves the best chance of conceiving, with intercourse three or four times every week being recommended. If that level of sexual activity has been more attainable since mid-March for more couples, there would surely be an increased pregnancy rate among those who are not using contraception.

You can add to that a surmise that anecdotal accounts of more alcohol being consumed at home, along with trade reports of a 40 per cent rise in take-home alcohol sales on the same period last year, may have increased sexual risk-taking and faulty use of contraceptives.

Since were living through what amounts to a social experiment, there is no knowing whether the psychological impact would make couples less or more likely to think about starting a family or, indeed, enlarging one.

On the one hand there is huge uncertainty about what sort of world you might be bringing a child into in nine months time, Ryan points out, on the other hand people can realise through all this what is important for them in life. Those who might have been putting off starting a family, may now feel the time has come, she suggests.

Up to now, the number of Irish women going on to have a third or fourth child has tended to keep the birth rate up in Ireland, says Fahey. Often it is the middle-class and professional women who are having the third and fourth child, which really is a bit unusual in international terms.

While immigrant women have accounted for a sizeable share of births in Ireland some 25 per cent of births in 2012 were to non-Irish mothers they tend to have fewer children than Irish women, he says, as many of them come from Eastern Europe where birth rates are lower and family sizes smaller than in Ireland.

This likelihood of the third or fourth child is one thing that Fahey thinks may change, not just due to the Covid-19 economic fallout but other pre-existing issues, such as the housing crisis.

A standout example in recent times of the impact mass uncertainty can have on a countrys birth rate is what happened in East Germany over the period of reunification with West Germany.

It is probably the most astonishing case study we have, says Dr Jo Murphy-Lawless, research fellow at NUI Galways Centre for Health Evaluation, Methodology Research and Evidence Synthesis.

Between 1989, the year the Berlin Wall fell, and 1991, a year after reunification, the number of births in the old GDR fell by 44 per cent, she reports. The completed fertility rate was 1.57 in 1989; by 1991 it was 0.8.

It didnt really begin to recover at all, only slightly, until the mid-1990s. It was almost as if women in East German, seeing the collapse of Communism, just gave up having children because of the absolute lack of confidence in their immediate futures.

Murphy-Lawless had a masters student who had lived in East Germany and who did her thesis on the experience of women there making the transition to a united Germany. Her research highlighted how the former GDR had given significant support to women as child bearers and child rearers, says Murphy-Lawless.

Somehow that shock of having to recalibrate their lives led to this colossal drop in fertility, unlike anything we have ever had. In general, we have been floating down.

Yet, she adds, we still seem to have quite a fondness for children in Ireland. We have the highest percentage of households with children in them in the EU, which is 40 per cent.

The impact possible long-term travel restrictions post Covid-19 might have on peoples decisions on family formation is something that Murphy-Lawless also muses about.

Global consumerism capitalism, which has been part and parcel of individualisation, has meant people have just moved on to greener pastures, be it for economic, career or lifestyle reasons. How easy it is going to be to do that now is the great unknown, she suggests.

If the opportunity and/or social pressure to see the world before starting a family is curtailed, that may have an effect if more people choose to settle down in Ireland now. There may be fewer stories originating from this period of going away for a year and ending up staying away for a lifetime.

The housing problem is a factor in the margins that Fahey has been considering as having implications for our birth rate. The traditional three-bed semi-detached was suitable for a three- or four-child family where a two-bedroom apartment is not.

Having a little garden out the front and the back makes having children a lot easier, he suggests indeed, never more so than right now.

The difficult of acquiring a long-term home in the first instance may deter people from starting families at all, he says or at least delay them, with possible repercussions for fertility the longer they wait. An inability to trade up to a bigger property might also deter couples from having a third or fourth child.

They were the factors that were there and, oddly enough, the indications are that maybe the current crisis will ease the housing problem, he says, pointing, for example to Airbnb properties coming onto the rental and sales markets.

Also, if the lack of capacity in the construction sector has hindered the building of new houses, he wonders if the inevitable stalling of plans for new hotels in the Dublin area over the next few years might free up a workforce to accelerate the numbers of homes being built.

This is a roundabout way in which a crisis like this could have an upside effect rather than a downside effect, he adds.

The closure of assisted reproduction clinics since the last week of March was devastating for couples in the midst of, or about to embark on, treatment. They have lost months in what some regard as a race against time.

We didnt get an absolute direction to close, says Dr John Kennedy, medical director of theSimsDublin and Cork and the RotundaIVF clinics. We closed because it was the right thing to do.

The health services were under huge pressure, he points out. However, he had been a little surprised at the European Society of Human Reproduction and Embryology (ESHRE) advising, in a statement on March 19th, that, as a precautionary measure against possible negative effects of Covid-19, all fertility patients should avoid becoming pregnant.

On April 23rd, the ESHRE rowed back on that, advising that, as infertility is a disease and with the risk of Covid-19 decreasing, all ART treatments can be restarted for any clinical indication, in line with local regulations.

At the time of writing, Kennedy is in the midst of planning for reopening the first week of May, with a new way of working, including extended opening hours to allow for social distancing through segregated team working and space in patient waiting areas. However, he adds, everything comes with an asterisk, as we are in uncharted waters.

That goes to Prof Fahey who has written extensively over the years on demographics: As with anything in this field, there are so many factors piling in together and they are not all pointing in the one direction of what the overall outcome will be.

Follow this link:
What have couples been doing in lockdown? We might know in nine months - The Irish Times

Cooperative Extension adapts to keep you informed – The Robesonian

I think it is safe to say we are all experiencing things we have never faced before. So, how are you doing?

I bet everyone is asking you a similar question these days. When I am asked that question, I say things like, I will be glad when this is over, or This is crazy, but we will get through it, or Im fine. In my head I am thinking, I am not doing fine at all. This is not okay.

Like everyone else, I am staying home for those who might not fare so well if they were to be infected with COVID-19. Then I remind myself, I am doing this for the greater good! But it is stressful! Our response to the situation we are in has been so quick, we have had no time to process what has happened to our very ordinary lives.

Many of us are trying to work from home and manage our families at the same time. Parents and caregivers are now homeschool teachers for the children in their homes. We are all trying to help each other understand what is going on in our world and how we can adapt to what we are all calling our new normal.

Businesses in town are having the same struggles. Finding the new routine and rhythm they need to meet the needs of the community and still provide those services while keeping everyone safe is a challenge. North Carolina Cooperative Extension, Robeson County Center, is no different. We are working hard to find new ways to connect to our clients and continue to give the research-based information we are known to provide. We know that many in our community do not have internet capabilities to get information from the World Wide Web. It is challenging for some, and others may be afraid to try new things. As Christopher Robin said to Winnie the Pooh, Youre braver than you believe, stronger that you seem, and smarter than you think.

You can embrace these new challenges and master them to keep informed and in touch with the things and people that are important in your life. Robeson County Cooperative Extension is committed to staying in touch! We will continue to broaden our scope of how we provide information as well as continue to provide the hands-on approaches you need. We are very interested in knowing what information you need from us and how you want to receive that information. We will be reaching out in a variety of ways to get feedback. Please dont hesitate to let us know what you need from Extension. We will continue to add to and update the ways you can get information from us.

Currently, you can find us on Facebook with live segments, titled Digging in with Extension, that highlight gardening information using our raised beds as the demonstration areas. You may have tuned in to see the daily egg-citing embryology segments by 4-H over the past month. New ideas for youth programming are being generated as quickly as possible and information will be available in the near future. The research many farmers depend on in our county for making planting decisions is continuing, and you can look forward to new and different ways of see those results very soon.

Follow us on Facebook at North Carolina Cooperative Extension, Robeson County Center. You can also check our website at http://robeson.ces.ncsu.edu/ for informative articles, links to resources and information, and (once we can gather again safely) upcoming events.

For more information, contact Christy Strickland, County Extension director, at 910-671-3276, by email at [emailprotected], or visit our website at http://robeson.ces.ncsu.edu/.

Christy Strickland is the county Extension director with North Carolina Cooperative Extension, Robeson County Center. She can be reached at 910-671-3276, or at [emailprotected]

See the article here:
Cooperative Extension adapts to keep you informed - The Robesonian

Coronavirus-hit mum gives birth to magic IVF baby six weeks premature in a hospital bereavement room – The Irish Sun

6

A MUM battling coronavirus has given birth to a "magic" IVF baby six weeks premature in a hospital bereavement room.

Claire Trusson, 37, fell pregnant after having IVF treatment following two years of struggling to start a family with husband Murray Mitchell, 33.

6

6

6

Just weeks before Claire was due, she started to experience cold-like symptoms which soon developed into a persistent cough.

She went into isolation, until she started experiencing contractions and was rushed to St Helier Hospital in Carshalton, near Sutton in South-West London.

While in hospital, medics had to put her in the most isolated room on the ward to keep her away from all others - which turned out to be the bereavement delivery room.

Claire went home and a day later tested positive for the virus - but found herself back in the bereavement suite just a week later on March 30 to safely give birth to baby Jake.

In the scheme of things, I am super lucky - I'm well, he's well and really it's amazing

The first-time mum said giving birth six weeks early while suffering from the virus was stressful, and she didn't expect to give birth in the bereavement room.

Claire said: "I found out this week that that's the bereavement room - that's where they put families with their stillborn babies so they can have some time with them.

"They have a memorial clock on the wall, and because I was timing my contractions when I was first in there, I spent a lot of time staring at that clock."

But she added that she was "really grateful" to have given birth to baby Jake and avoid "another six weeks of anxiety of what giving birth would look like".

She added: "In the scheme of things, I am super lucky - I'm well, he's well and really it's amazing."

What is IVF Treatment?

After struggling to conceive for two years, Claire and her husband received IVF on the NHS and a single egg was implanted in August 2019.

IVF is one of the most successful fertility treatments, and has given birth to 8 million babies worldwide.

The success rate is dependent on multiple factors, and range from 7 per cent to 29 per cent, according to the Human Fertilisation and Embryology Authority.

But despite her joy at having baby Jake, Claire is still concerned about passing the virus onto him due to a lack of face masks.

On the way home from hospital, Jake met his grandmother Angela and uncle David through the car window.

'DRY AND SUNNY'Sat to be hottest day of year so far as Met Eireann say temps to hit 20C

Revealed

DRAFT PLANSize of some pubs & how many punters will be allowed in under new plan to reopen

GETTING BETTER17,110 people diagnosed with Covid-19 in Ireland 'have recovered'

COVID CASHCovid-19 payments could be cut to make more affordable, Finance Minister warns

banking on a holSpecial Bank Holiday on the cards to help Ireland out of Covid-19 pandemic

She added: "Every little sneeze and every little cough and every little cry, I jump on him like, 'oh god, you've got coronavirus.'

"It sounds really reckless, but it's really hard to look after a baby and them not see your face - and I didn't really have any face masks."

"I'm just trying not to breathe on him."

6

6

Give now to The Sun's NHS appeal

BRITAINs four million NHS staff are on the frontline in the battle against coronavirus.

But while they are helping save lives, who is there to help them?

The Sun has launched an appeal to raise 1MILLION for NHS workers. The Who Cares Wins Appeal aims to get vital support to staff in their hour of need.

We have teamed up with NHS Charities Together in their urgent Covid-19 Appeal to ensure the money gets to exactly who needs it.

The Sun is donating 50,000 and we would like YOU to help us raise a million pounds, to help THEM. No matter how little you can spare, please donate today here: http://www.thesun.co.uk/whocareswinsappeal.

CORONAVIRUS CRISIS - STAY IN THE KNOW

Don't miss the latest news and figures - and essential advice for you and your family.

To receive The Sun's Coronavirus newsletter in your inbox every tea time, sign up here.To follow us on Facebook, simply 'Like' our Coronavirus page.

Get Britain's best-selling newspaper delivered to your smartphone or tablet each day - find out more.

We pay for your stories! Do you have a story for The Sun Online news team? Email us at tips@the-sun.co.uk or call 0207 782 4368 . You can WhatsApp us on 07810 791 502. We pay for videos too. Click here to upload yours.

See the original post:
Coronavirus-hit mum gives birth to magic IVF baby six weeks premature in a hospital bereavement room - The Irish Sun

The Role of Microphysiological Systems for Oncology and Stem Cell Research – News-Medical.net

Sponsored Content by PittconMay 6 2020

In this interview, Dr. Nancy Allbritton from The Allbritton Lab talks to News-Medical and Life Sciences about the revolutionary technology and techniques for the application of new technologies for oncology and stem cell research.

Dr. Nancy Allbritton provides insight into the organ-on-a-chip and the ability it has to monitor and control the environment at the cellular and tissue level is one of the most promising applications for microengineered systems. Dr Allbritton will be presenting her research and findings at Pittcon 2020 in Chicago.

Microphysical systems seek to replicate the smallest functioning unit of an organ. For intestine-on-a-chip, it might be large or small intestinal crypts. For a heart, it may be a section of contractile muscle. For the liver, it may be a liver lobule or group of lobules. It's a group of interconnected cells so that they are not just behaving as a single cell or just a small cluster, but they began to show higher-order behavior and functioning.

I think one of the reasons microphysical systems are becoming increasingly important is that we've had a lot of breakthroughs in stem cell technology. The ability to grow human stem cells from different organs is now present, as well as the ability to create a tissue of differentiated cell types from primary stem cells or organ-specific cells from induced pluripotent stem cells.

Right now, it is the perfect time for this technology, because we have all the enabling microfabrication methods and stem cell biology innovations coming together. Another reason organs-on-chips are becoming important is the ability to grow human tissue. It's very hard to do experiments on the human population and get a good representation of the population, either because people aren't volunteering or because there just aren't enough people in that particular group of individuals. With the chip, you can begin to sample population-wide tissue variation. Organs on chips can also be a better way to test drugs. Rather than testing cells in a dish, which are usually tumor cells and very abnormal in their growth and other characteristics, organs-on-chips constructed from normal human cells can be used to get a more accurate representation of how drugs will affect humans. Additionally, they may outperform murine experiments in many ways since humans are not simply 70 kg mice.

We have been able to cure mice of all sorts of diseases, but much of this work hasnt translated to humans. So, while that was a good screening technology, a lot of drugs got through that were quite toxic to humans, and then a lot of drugs that may have worked well in humans, but were toxic to mice got blocked.

Image Credit:Shutterstock/royaltystockphoto.com

Microphysiologic devices should maximize the number of good drugs that could work well in humans. You can hopefully also get higher value information and create a much better drug pipeline. I think doing high-throughput screening on organ subunits on microfabricated devices can complement drug screening in humans. The idea is that you may be able to cut costs in several ways;

I believe you can also begin to develop human disease models. You can create mouse models of human disease, but they almost never completely recapitulate human disease. Even when it is a simple genetic mutation, the mice can often be asymptomatic or present with different symptoms and outcomes to that mutation. With the organ-on-a-chip, you can have functioning human tissue that mimics many of the symptoms of human diseases. Even more exciting, one can begin to put, for example, an intestine-on-chip coupled with the human gut microbiome or the gut flora and begin to understand how the tissue and microbiota interact.

This is important because our gut flora is very different from that of a mouse and other model organisms. We now know that intestinal microbes have a tremendous physiologic impact throughout our body including metabolism and mentation, our feeding behavior, and these are aspects of human behavior or physiology that can't be recapitulated in an animal model or cells in a dish.

Eventually, we'll be able to string human organs together as human organ-on-chip systems. For example, food is added to the gut model and absorbed, the nutrients travel to the liver, the liver metabolizes the absorbed compounds sending them out to the body as a whole including the brain and heart. The organs must be tied together to see the full effect in which the behavior or functioning of one organ impacts other connected organs. That will never replace a fully functioning human, but I think the expectation is that it may end up being a lot more accurate and, in some ways, cheaper than mice or other model mammalian systems.

The organ-on-a-chip systems will help us understand basic biology and the basic physiology of the human.

Microphysiologic devices depend on many fields of chemistry for their advancement including synthetic organic, polymer and analytical chemistry. We need more synthetic matrices to support cells and tissues including smart polymers and scaffolding materials that will support, direct and shape these organ systems. Right now, people often use matrices derived from native biologic materials, like collagen or matrigel, which are expensive and not fully defined. Polymer chemists and synthetic chemists are working hard to develop novel materials and matrices while analytical chemists, as well as engineers, are developing materials and methods for microdevice fabrication, sensor enhancements, and other device-related innovations.

Microphysiologic systems will clearly need an array of embedded and external sensors to monitor their health and well-being as well as pathophysiologic attributes. They will need robust, reliable (and often miniaturized) embedded sensors for oxygen consumption, glucose concentration, CO2 production, pH, and other chemical and physical attributes. Importantly the sensors should not perturb the system. These sensors will likely require external instrumentation or detection methods to monitor the embedded sensors, for example, RFID or optical readouts.

For engineering and chemistry, these are going to be huge areas where many can contribute to moving the field forward. For engineering, specifically, developing ways to make integrated systems that are efficient, low cost, manufacturable, shippable, self-contained, and can talk to each other will be important. This is an area where engineering and chemistry must work together in a team approach to move the field forward. It's going to take both disciplines to really advance the field.

Microfabricated technology refers to devices developed with micron-sized features. Cells have diameters on the order of 10 microns and many organ subunits span hundreds of microns so that micron-sized architectural features are required to recapitulate key features. For example, large intestinal crypts (the key physiologic subunit of the large intestine) is approximately 400 microns in length and 100 microns wide with the stem cell niche spanning tens of microns. Thus, microfabrication methods are perfect for rebuilding many of the key architectural features of the large intestine.

When it comes to rebuilding architectural features such as the lare intestine, microfabrication methods are perfect for this. Image Credit:Shutterstock/nobeastsofierece

We do intestine-on-a-chip, which is mostly the large intestine and have several platforms of varying complexity. The simplest is the human intestinal epithelial monolayers that have a stem and/or differentiated cells. These can be used to assess how the intestine transports and metabolizes drugs and nutrients or how the stem cells differentiate into mucus-producing, hormone-producing, or absorptive cell types. These systems are designed to be higher throughput model systems that are simple but do not possess the greatest possible information content. However, they are robust and reliable. We also have complex 3D tissues that replicate a wide range of physiologic behaviors as well as the architectural features of the human intestine. Importantly many of these systems will support the wide array of chemical and gas gradients found in the human intestine. They can also host the human microbiome so that a better understanding of the complex interplay between the human cells and microbes can be developed in both health and disease.

As with all of our model systems, we usually advise users of our systems to employ the simplest platform possible and then add in complexity as needed for the task at hand.

We have more complex platforms that are designed to replicate a lot of the different features of the human intestine, such as the architecture, cell migration behaviors, and stem cell fate decisions. These are shaped three-dimensional systems that exist as arrays of crypts (or microwells) covered with a monolayer of intestinal epithelial cells. The crypt array has a basal surface for a nutrient diffusion, and a lumen, like the inside of the intestine.

You can imagine the cells on the inside of the intestine, facing the waste or food, are very different from the cells that are at the base of the intestinal crypts. In these systems, the stem cells are found at the crypt or microwell base while the differentiated, mature cells such as absorptive cells are found facing the luminal surface, i.e. waste side. These systems are chemically and architecturally much more faithful duplicates of the human intestine than the simpler systems, but that also means they're a little harder to create, build, and maintain. With some of these three-dimensional systems, we create chemical gradients across the tissues, i.e. the long axis of the intestinal crypt, just as stem cell factors and food/bacterial metabolites exists in a gradient across your intestinal crypts. This microdevice permits very sophisticated micro-environmental control of these complex tissues.

We can do a lot of it, but we can't do it all. For example, with the chemical gradients, the stem cells that sit at the base of these microwells are exposed to very high growth factors, but about 400 microns away, so a few hair diameters, the cells don't see much of these factors. This chemical gradient mimics the signaling microenvironment of the intestine very closely. There are also all sorts of bacterial metabolites and products that are at very high concentration for the cells at the luminal surface, but low where the stem cells are down at the base of the microwells or crypts. We can also replicate these food and bacterial metabolite gradients by using purified compounds or actual bacteria on the luminal side of the intestine on a chip.

This 3D system begins to duplicate the human physiologic signals that control the cells behavior, but there are some things we cannot do yet. We don't have a blood supply, for example, or blood vessels going into our chip. Thats one of the next steps, but there is a lot of work to do to build it, yet still have a robust and reliable intestine-on-chip system. Our tissue is growing in complexity, but we still only have 1 to 2 tissues on the devices and a small subset of the bacteria found in the human intestine. One could imagine increasingly putting more and more tissue types. The intestine has epithelial cells, fibroblasts, muscle cells, neural cells, immune cells, all sorts of other cell types, and adding in all of those cell types would create a more normal physiologic organ. I think those are all goals for the future on which we will be moving forward.

Our intestinal-on-chip technologies can be used to understand drug transport and metabolism by humans (as opposed to mice or tissue-cultured tumor cells). Additionally, the microbes in the human intestine or the human intestinal epithelium can convert drugs into their active form or into a toxic metabolite. Along that line, one could begin to do rapid screens as to how drugs are modified, metabolized and transported across the intestinal epithelium. Importantly many drugs cause intestinal dysfunction or side effects and screens can be performed for the impact of the drugs on the intestinal cells themselves and the impact on intestinal barrier function, e.g. leakiness.

As an example, it's now also clear that in cancer chemotherapy, the gut and the bacteria within the gut play a huge role in how well the chemotherapy is working. How this works is not well understood, so I think there's going to be a big push to use these systems to understand how we can make anti-cancer drugs that are more effective and less toxic on the gut and other biological systems. We are only beginning to scratch the surface.

Image Credit:Shutterstock/ nobeastsofierce

I dont think microphysiological systems can ever totally replace animal models. It's the law in the US to test drugs on animals. We are also a long way off from having a full human-on-a-chip with all of the different organ systems in place and interconnected, whereas a mouse or other animal system is already there. I think it's more likely that the chips will reduce the number of animals used so that you can get higher value information, thereby complementing rather than replacing animal models. The chips will also enable insights as to how humans might ultimately respond differently from animal model systems.

On-going work in the organ-on-chip area is to demonstrate that these devices actually mimic and replicate human responses (and many have already been shown to mimic human physiology when animal models failed). Overall the future for organ-on-chip technologies appears quite bright and will undoubtedly grow in future importance and impact.

There are already devices that demonstrate many of the complex disease phenotypes. For example, blood vessels on-chip have replicated blood vessel diseases such as atherosclerosis and tumor metastases. There are some amazing heart-on-chip devices with functioning cardiac tissue subunits that accurately recapitulate the impact of cardiovascular drugs, so I think we are making good progress. I think that we will see a growing number of impressive and highly predictive disease models as time goes by.

Near term, our big goal is to really make an intestine-on-a-chip that fully replicates the human small and large intestines. We're working hard at putting a human microbiome or normal intestinal bacteria on our intestine-on-chip. In addition to chemical gradients, gas gradients such as oxygen exist across the intestinal crypts which we're working hard at replicating. We really want to add in more tissue types, such as the immune system, fibroblasts, and nervous tissue. We've got quite a bit of work to do to make a fully functioning replica so we are also starting to team up with other people, particularly liver-on-a-chip people so that our intestine-on-a-chip can absorb food and then send it to their liver-on-chip to create a fully functioning liver-intestinal model to recapitulate food digestion, metabolism, and detoxification.

A big part of our work is to make the systems robust and reliable as well as easy to use for biologists and clinical investigators. That may sound trivial, but it's not. A lot of great devices remain isolated in the inventors' lab due to their high degree of complexity. When biologists try to use these complex devices, there are just too many failure points. Even to make one of these systems shippable will be a challenge, because how do you give it to FedEx, yet arrive in good condition across the world? There are a lot of challenges with scalability, manufacturing, robustness, and reliability that my lab, in particular, is interested in tackling to make sure that these organ-on-chips get out into the real world and fulfill their potential.

To find out more please visit http://allbritton.web.unc.edu/

Dr. Allbritton is a Professor in the Department of Bioengineering and the Frank & Julie Jungers Dean of Engineering at the University of Washington in Seattle. She has been the scientific founder of four companies and enjoys international travel.

Link:
The Role of Microphysiological Systems for Oncology and Stem Cell Research - News-Medical.net

Broad Foundation brings together stem cell scientists, engineers and physicians at University of Southern – Mirage News

The Broad Foundation brings together stem cell scientists, engineers and physicians at USC and beyond

Developing new stem cell therapies requires more than a solo biologist having a eureka moment alone in the lab. Real progress relies on collaborations between biologists, engineers and physicians. Thats why The Eli and Edythe Broad Foundation has continued its support of two strategic initiatives: innovation awards bringing together teams of engineers and scientists from USC and Caltech, and clinical research fellowships for physician-scientists.

Engineering new approaches: The Broad Innovation Awards

For the fifth consecutive year, the Broad Innovation Awards are providing critical funding to USC-affiliated faculty members pursuing multi-investigator research collaborations related to stem cells. For the first year, these collaborations are also drawing on the expertise of biomedical engineers from Caltech. Each award provides $200,000 of funding for a one-year project.

Were very excited to be joining our colleagues at USC in pioneering new approaches to advancing stem cell research, said Stephen L. Mayo, chair of the Division of Biology and Biological Engineering at Caltech. Were thankful to The Broad Foundation for supporting cross-town collaborations between scientists with different expertise but common goals.

With support from a Broad Innovation Award, Andy McMahon, the director of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC, is collaborating with Caltech biomedical engineer Long Cai to leverage a new technology for understanding chronic kidney disease. The technology, called seqFISH, provides information about genetic activity taking place in intact tissueenabling the study of the interactions between cells in their native environments.

Dr. Cais seqFISH technology will provide an unprecedented insight into the cellular interplay underlying chronic kidney disease caused by a maladaptive response to acute kidney injury, said McMahon, who is the W.M. Keck Provost and University Professor of Stem Cell Biology and Regenerative Medicine, and Biological Sciences, as well as the chair of the Department of Stem Cell Biology and Regenerative Medicine at USC. We aim to better understand this maladaptive responsewhich is more common in malesin order to find new targets for preventing the progression to chronic kidney disease.

A second Broad Innovation Award brings together USC Stem Cell scientist Rong Lu and Caltech synthetic biologist Michael Elowitz. Their team will study the spatial organization of blood-forming stem and progenitor cells, also called hematopoietic stem and progenitor cells (HSPCs), which reside in the bone marrow. By pinpointing the locations of specific HSPCs, the scientists may find clues to explain why certain HSPCs are so dominantreplenishing the majority of the bodys blood and immune cells after a disruption such as a bone marrow transplantation.

Spatial advantages may be the primary drivers of what we refer to as the clonal dominance of certain HSPCs, said Lu, a Richard N. Merkin Assistant Professor of Stem Cell Biology and Regenerative Medicine, Biomedical Engineering, Medicine, and Gerontology at USC. Understanding the spatial competition between HSPCs could help improve bone marrow transplantation and provide new insights into aging and the development of diseases such as leukemiawhich are associated with clonal dominance.

Elowitz added: Thanks to the Broad Innovation Award and this exciting collaboration with Rong Lu, we will be able to bring a new, synthetic biology approach to record cell histories and read them out in individual cells within their native spatial context, providing new insights into fundamental questions in blood stem cell development.

A third Broad Innovation Award brings together three collaborators at USC: Michael Bonaguidi, an assistant professor of stem cell biology and regenerative medicine, biomedical engineering, and gerontology; Robert Chow, a professor of physiology and neuroscience, and biomedical engineering; and Jonathan Russin, an assistant professor of neurological surgery and associate surgical director for the USC Neurorestoration Center. Their project focuses on finding new approaches to treating epilepsy by studying neural cells called astroglia. These cells perform a variety of key functions that support the health of neurons in the brain, and they may also play a role in modulating epileptic seizures.

Although adults dont tend to generate many new brain cells, humans do produce a limited number of new astroglia, said Bonaguidi. We will examine these newborn astroglia at the single-cell level to better understand their role in epileptic patients, and to lay the groundwork for identifying new treatments.

The doctors are in: The Broad Clinical Research Fellowships

The Broad Clinical Research Fellowships are also entering their fifth consecutive year. These fellowships support stem cell research by physician-scientists and residents who intend to practice medicine in California.

These fellowships provide a very special opportunity for our medical residents to engage deeply in laboratory research, as a complement to their extensive training in patient care, said Laura Mosqueda, Dean of the Keck School of Medicine of USC. This valuable research experience gives them a much more complete perspective on how to meet the challenges of finding the best possible treatments for their patients.

A USC resident physician in general surgery, Kemp Anderson will spend his fellowship studying necrotizing enterocolitis, a very serious intestinal infection that affects nearly 10 percent of premature infants. Specifically, he will explore how a molecule involved in cellular communication, called farnesoid X receptor, or FXR, might contribute to this disease.

If FXR plays a role in compromising intestinal barrier function in these premature infants, then altering the activity of FXR could potentially yield treatment modalities for necrotizing enterocolitis, avoiding the morbidity and mortality associated with surgical intervention, said Anderson, who is performing the research under the mentorship of Christopher Gayer and Mark Frey at Childrens Hospital Los Angeles (CHLA). Im deeply appreciative of the benefactors and the selection committee for awarding me the Broad Clinical Fellowship, as it is allowing me devoted time to focus on this important project, and to become a more well-rounded physician through this academic pursuit.

Brittany Rocque, a resident physician in general surgery, will use her fellowship to seek better ways to predict, detect and diagnose immune rejection in patients who have undergone liver transplantation. Nearly 60 percent of pediatric patients and at least 15 percent of adult patients reject their liver transplants, and this can currently only be confirmed through an invasive surgical biopsy. Rocque is utilizing the technology Imaging Mass Cytometry to identify and analyze the types of immune cells involved in rejection.

My project has the potential to provide a noninvasive option to assess rejection in transplanted patients, and to expand our understanding of immune rejection, said Rocque, who is being co-mentored by Juliet Emamaullee and Shahab Asgharzadeh at CHLA. Im greatly looking forward to applying my passion for transplantation surgery in the context of basic science, and enhancing my appreciation for the nuances of research, thanks to the Broad Clinical Research Fellowship.

A hematology-oncology fellow who will be transitioning to a junior faculty position at USC next year, Caitlin ONeill will study a condition known as clonal hematopoiesis or CH, a phenomenon common in the aging population. CH involves genetic mutations that cause the expansion of a particular population of blood cells without leukemia or related malignancies. CH increases risks for certain health conditions including heart disease.

During her Broad Clinical Research Fellowship, ONeill will look at one mutation seen in patients with CH: a mutation to the gene called Tet methylcytosine dioxygenase 2, or TET2. ONeill will explore if this mutation promotes blood clots, inflammation and heart disease.

The goal is to inform therapies to prevent heart disease and leukemic progression in aging patients with CH, said ONeill, who is working with co-mentors Casey OConnell and Rong Lu at USC. Im very happy to be working on this project, with support from the Broad Clinical Research Fellowship, during my transition to becoming a faculty member at USC.

See the original post here:
Broad Foundation brings together stem cell scientists, engineers and physicians at University of Southern - Mirage News

Cell Biology Cloud Computing Market Development, Market Trends, Key Driven Factors, Segmentation And Forecast To 2020-2026| Accenture, Amazon Web…

Latest Report On Cell Biology Cloud Computing Market including Market Landscape, and Market size, Revenues by players, Revenues by regions, Average prices, Competitive landscape, market Dynamics and industry trends and developments during the forecast period.

The global Cell Biology Cloud Computing market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Cell Biology Cloud Computing market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global market. The authors of the report profile leading companies of the global Cell Biology Cloud Computing market, Also the details about important activities of leading players in the competitive landscape.

Key companies operating in the global Cell Biology Cloud Computing market include: , Accenture, Amazon Web Services, Benchling, Cisco Systems, Dell Emc, IBM, DXC Technology, Oracle, ScaleMatrix, IPERION, NovelBio

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1664672/global-cell-biology-cloud-computing-market

The report predicts the size of the global Cell Biology Cloud Computing market in terms of value and volume for the forecast period 2020-2026. As per the analysis provided in the report, the global Cell Biology Cloud Computing market is expected to rise at a CAGR of xx % between 2020 and 2026 to reach a valuation of US$ xx million/billion by the end of 2026. In 2020, the global Cell Biology Cloud Computing market attained a valuation of US$ XX million/billion. The market researchers deeply analyze the global Cell Biology Cloud Computing industry landscape and the future prospects it is anticipated to create

Segmental Analysis

The report has classified the global Cell Biology Cloud Computing industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Cell Biology Cloud Computing manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Cell Biology Cloud Computing industry.

Global Cell Biology Cloud Computing Market Segment By Type:

, Public Cloud Computing, Private Cloud Computing, Hybrid Cloud Computing

Global Cell Biology Cloud Computing Market Segment By Application:

,Genomics, Diagnostics, Clinical Trials, Pharma Manufacturing, Others

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Cell Biology Cloud Computing industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Cell Biology Cloud Computing market include: , Accenture, Amazon Web Services, Benchling, Cisco Systems, Dell Emc, IBM, DXC Technology, Oracle, ScaleMatrix, IPERION, NovelBio

Key questions answered in the report:

Enquire for Customization in the report @ https://www.qyresearch.com/customize-request/form/1664672/global-cell-biology-cloud-computing-market

TOC

1 Market Overview of Cell Biology Cloud Computing1.1 Cell Biology Cloud Computing Market Overview1.1.1 Cell Biology Cloud Computing Product Scope1.1.2 Market Status and Outlook1.2 Global Cell Biology Cloud Computing Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Cell Biology Cloud Computing Market Size by Region (2015-2026)1.4 Global Cell Biology Cloud Computing Historic Market Size by Region (2015-2020)1.5 Global Cell Biology Cloud Computing Market Size Forecast by Region (2021-2026)1.6 Key Regions Cell Biology Cloud Computing Market Size YoY Growth (2015-2026)1.6.1 North America Cell Biology Cloud Computing Market Size YoY Growth (2015-2026)1.6.2 Europe Cell Biology Cloud Computing Market Size YoY Growth (2015-2026)1.6.3 China Cell Biology Cloud Computing Market Size YoY Growth (2015-2026)1.6.4 Rest of Asia Pacific Cell Biology Cloud Computing Market Size YoY Growth (2015-2026)1.6.5 Latin America Cell Biology Cloud Computing Market Size YoY Growth (2015-2026)1.6.6 Middle East & Africa Cell Biology Cloud Computing Market Size YoY Growth (2015-2026)1.7 Coronavirus Disease 2019 (Covid-19): Cell Biology Cloud Computing Industry Impact1.7.1 How the Covid-19 is Affecting the Cell Biology Cloud Computing Industry

1.7.1.1 Cell Biology Cloud Computing Business Impact Assessment Covid-19

1.7.1.2 Supply Chain Challenges

1.7.1.3 COVID-19s Impact On Crude Oil and Refined Products1.7.2 Market Trends and Cell Biology Cloud Computing Potential Opportunities in the COVID-19 Landscape1.7.3 Measures / Proposal against Covid-19

1.7.3.1 Government Measures to Combat Covid-19 Impact

1.7.3.2 Proposal for Cell Biology Cloud Computing Players to Combat Covid-19 Impact 2 Cell Biology Cloud Computing Market Overview by Type2.1 Global Cell Biology Cloud Computing Market Size by Type: 2015 VS 2020 VS 20262.2 Global Cell Biology Cloud Computing Historic Market Size by Type (2015-2020)2.3 Global Cell Biology Cloud Computing Forecasted Market Size by Type (2021-2026)2.4 Public Cloud Computing2.5 Private Cloud Computing2.6 Hybrid Cloud Computing 3 Cell Biology Cloud Computing Market Overview by Type3.1 Global Cell Biology Cloud Computing Market Size by Application: 2015 VS 2020 VS 20263.2 Global Cell Biology Cloud Computing Historic Market Size by Application (2015-2020)3.3 Global Cell Biology Cloud Computing Forecasted Market Size by Application (2021-2026)3.4 Genomics3.5 Diagnostics3.6 Clinical Trials3.7 Pharma Manufacturing3.8 Others 4 Global Cell Biology Cloud Computing Competition Analysis by Players4.1 Global Cell Biology Cloud Computing Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cell Biology Cloud Computing as of 2019)4.3 Date of Key Manufacturers Enter into Cell Biology Cloud Computing Market4.4 Global Top Players Cell Biology Cloud Computing Headquarters and Area Served4.5 Key Players Cell Biology Cloud Computing Product Solution and Service4.6 Competitive Status4.6.1 Cell Biology Cloud Computing Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Accenture5.1.1 Accenture Profile5.1.2 Accenture Main Business and Companys Total Revenue5.1.3 Accenture Products, Services and Solutions5.1.4 Accenture Revenue (US$ Million) (2015-2020)5.1.5 Accenture Recent Developments5.2 Amazon Web Services5.2.1 Amazon Web Services Profile5.2.2 Amazon Web Services Main Business and Companys Total Revenue5.2.3 Amazon Web Services Products, Services and Solutions5.2.4 Amazon Web Services Revenue (US$ Million) (2015-2020)5.2.5 Amazon Web Services Recent Developments5.3 Benchling5.5.1 Benchling Profile5.3.2 Benchling Main Business and Companys Total Revenue5.3.3 Benchling Products, Services and Solutions5.3.4 Benchling Revenue (US$ Million) (2015-2020)5.3.5 Cisco Systems Recent Developments5.4 Cisco Systems5.4.1 Cisco Systems Profile5.4.2 Cisco Systems Main Business and Companys Total Revenue5.4.3 Cisco Systems Products, Services and Solutions5.4.4 Cisco Systems Revenue (US$ Million) (2015-2020)5.4.5 Cisco Systems Recent Developments5.5 Dell Emc5.5.1 Dell Emc Profile5.5.2 Dell Emc Main Business and Companys Total Revenue5.5.3 Dell Emc Products, Services and Solutions5.5.4 Dell Emc Revenue (US$ Million) (2015-2020)5.5.5 Dell Emc Recent Developments5.6 IBM5.6.1 IBM Profile5.6.2 IBM Main Business and Companys Total Revenue5.6.3 IBM Products, Services and Solutions5.6.4 IBM Revenue (US$ Million) (2015-2020)5.6.5 IBM Recent Developments5.7 DXC Technology5.7.1 DXC Technology Profile5.7.2 DXC Technology Main Business and Companys Total Revenue5.7.3 DXC Technology Products, Services and Solutions5.7.4 DXC Technology Revenue (US$ Million) (2015-2020)5.7.5 DXC Technology Recent Developments5.8 Oracle5.8.1 Oracle Profile5.8.2 Oracle Main Business and Companys Total Revenue5.8.3 Oracle Products, Services and Solutions5.8.4 Oracle Revenue (US$ Million) (2015-2020)5.8.5 Oracle Recent Developments5.9 ScaleMatrix5.9.1 ScaleMatrix Profile5.9.2 ScaleMatrix Main Business and Companys Total Revenue5.9.3 ScaleMatrix Products, Services and Solutions5.9.4 ScaleMatrix Revenue (US$ Million) (2015-2020)5.9.5 ScaleMatrix Recent Developments5.10 IPERION5.10.1 IPERION Profile5.10.2 IPERION Main Business and Companys Total Revenue5.10.3 IPERION Products, Services and Solutions5.10.4 IPERION Revenue (US$ Million) (2015-2020)5.10.5 IPERION Recent Developments5.11 NovelBio5.11.1 NovelBio Profile5.11.2 NovelBio Main Business and Companys Total Revenue5.11.3 NovelBio Products, Services and Solutions5.11.4 NovelBio Revenue (US$ Million) (2015-2020)5.11.5 NovelBio Recent Developments 6 North America Cell Biology Cloud Computing by Players and by Application6.1 North America Cell Biology Cloud Computing Market Size and Market Share by Players (2015-2020)6.2 North America Cell Biology Cloud Computing Market Size by Application (2015-2020) 7 Europe Cell Biology Cloud Computing by Players and by Application7.1 Europe Cell Biology Cloud Computing Market Size and Market Share by Players (2015-2020)7.2 Europe Cell Biology Cloud Computing Market Size by Application (2015-2020) 8 China Cell Biology Cloud Computing by Players and by Application8.1 China Cell Biology Cloud Computing Market Size and Market Share by Players (2015-2020)8.2 China Cell Biology Cloud Computing Market Size by Application (2015-2020) 9 Rest of Asia Pacific Cell Biology Cloud Computing by Players and by Application9.1 Rest of Asia Pacific Cell Biology Cloud Computing Market Size and Market Share by Players (2015-2020)9.2 Rest of Asia Pacific Cell Biology Cloud Computing Market Size by Application (2015-2020) 10 Latin America Cell Biology Cloud Computing by Players and by Application10.1 Latin America Cell Biology Cloud Computing Market Size and Market Share by Players (2015-2020)10.2 Latin America Cell Biology Cloud Computing Market Size by Application (2015-2020) 11 Middle East & Africa Cell Biology Cloud Computing by Players and by Application11.1 Middle East & Africa Cell Biology Cloud Computing Market Size and Market Share by Players (2015-2020)11.2 Middle East & Africa Cell Biology Cloud Computing Market Size by Application (2015-2020) 12 Cell Biology Cloud Computing Market Dynamics12.1 Industry Trends12.2 Market Drivers12.3 Market Challenges12.4 Porters Five Forces Analysis 13 Research Finding /Conclusion 14 Methodology and Data Source 14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Disclaimer14.4 Author List

About Us

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the original post:
Cell Biology Cloud Computing Market Development, Market Trends, Key Driven Factors, Segmentation And Forecast To 2020-2026| Accenture, Amazon Web...

Single Cell Multi-Omics Market to Witness Robust Expansion by 2025 – Cole of Duty

Market Research Vision announces addition of new report Single Cell Multi-Omics Market Report: Regional Data Analysis by Production, Revenue, Price, Gross Margin, and Forecast to 2025 to its database.

The Report on Covid-19 Impact on Single Cell Multi-Omics Market which provide detailed study of impact of the novel Coronavirus (COVID-19) pandemic on the historical and present/future market data.

The Single Cell Multi-OmicsMarket globally is a standout among st the most emergent and astoundingly approved sectors. This worldwide market has been developing at a higher pace with the development of imaginative frameworks and a developing end-client tendency.The worldwide Single Cell Multi-Omicsmarket is an enlarging field for . This report gives an exhaustive appraisal of the Single Cell Multi-Omicsmarket driving components, which are perceived reliant on the requests of end-client, variable changes in the market, preventive components, and administrative understanding.

Get a Sample Report About COVID-19s Impact On This Market:@ https://www.marketresearchvision.com/request-sample/431939

Major Manufacturer Detail:, 10x Genomics, 1CellBio, MissionBio, NanoString Technologies, Fluidigm Corporation, Fluxion Biosciences, Bio-Rad Laboratories, Celsee, BGI Genomics, GE LifeSciences, Illumina, Takara Bio, QIAGEN N.V.

Product Types Detail: Single Cell Genomics, Single Cell Proteomics, Single Cell Transcriptomics, Single Cell Metabolomics, ),

Major Application Oncology, Cell Biology, Neurology, Immunology, Others),

The Single Cell Multi-Omicsmarket is the cornerstone of the general improvement conditions and desires, as the development of a specific idea needs different analysis, activities, estimates, and philosophies mechanically.

We conveyed a point by point outline of the whole key Single Cell Multi-Omicsmarket players who have significant score concerning demand, revenue, and deals through their solid administrations. The global Single Cell Multi-Omicsmarket report illustrates the profound outline of existing developments, particulars, parameter, and creation. The Single Cell Multi-Omicsmarket likewise conveys a total survey of the money related exciting ride in regards to request rate and satisfaction extents.

Click here to Get customization & check discount for the report @ https://www.marketresearchvision.com/check-discount/431939

Regional Overview

The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South America after evaluating political, economic, social and technological factors affecting the market in these regions.

Market Research Visionhas been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

Comparative Analysis:

The report also includes the profiles of key Single Cell Multi-Omics Market companies along with their SWOT analysis and market strategies. In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

Get Detailed Information About COVID-19s Impact On This Market:@ https://www.marketresearchvision.com/reports/431939/Single-Cell-Multi-Omics-Market

More here:
Single Cell Multi-Omics Market to Witness Robust Expansion by 2025 - Cole of Duty